Summary: In the multiple-dose portion of a phase 1 study, laroprovstat added to rosuvastatin lowered LDL cholesterol versus placebo by 29% at 1 mg and 51% at 30 mg over 28 days. The approximately 80% reduction from untreated baseline with the higher-dose combination includes the preceding statin effect; safety and tolerability were the primary objective.
PICO Summary
| Element | Detail |
|---|---|
| Population | Healthy adults aged 18-55 in a phase 1 programme with separate single-dose and multiple-dose cohorts. The multiple-dose safety population comprised 60 treated participants: 20 at 1 mg, 18 at 30 mg and 22 placebo. Entry LDL cholesterol was 100-190 mg/dL before rosuvastatin; progression required at least a 30% LDL reduction after at least two weeks of the run-in. Participants were treatment-naive before, not after, that run-in. |
| Intervention | Oral laroprovstat 1 mg daily (n=20) or 30 mg daily (n=18) for 28 days, following at least three weeks of rosuvastatin 20 mg, which continued as background treatment. Separate single-dose cohorts investigated pharmacokinetics and food effects. |
| Comparator | Placebo for 28 days with background rosuvastatin 20 mg, n=22 treated. The LDL comparison was not against no treatment and not against another PCSK9 inhibitor. |
| Outcomes | Primary objective: safety and tolerability. During multiple dosing, at least one adverse event occurred in 13/38 (34.2%) active-treatment participants versus 8/22 (36.4%) placebo; drug discontinuation for adverse events occurred in 3/38 (7.9%) versus 1/22 (4.5%). No deaths or serious adverse events were reported. Discontinuations included nonsustained ventricular tachycardia in one 30-mg recipient and one placebo recipient, atrioventricular block in one 1-mg recipient, and ALT above three times the upper limit without bilirubin elevation in another 1-mg recipient. LDL lowering was a secondary pharmacodynamic outcome: placebo-corrected reductions of 29% (95% CI 18%-38%) and 51% (95% CI 44%-58%) at 1 and 30 mg. Approximate reductions from untreated baseline of 70% and 80% include rosuvastatin's preceding effect and are not placebo-corrected laroprovstat monotherapy effects. |
| Study Design | Original 2026 phase 1 publication, NCT05384262, described by the authors as randomised, single-blind and placebo-controlled; includes preclinical work plus distinct single- and multiple-dose human cohorts. AstraZeneca funded the study, with many employee/shareholder authors. The multiple-dose demographic paragraph describes 62 people, but treated arm counts and safety denominators sum to 60; the article uses the explicitly reported treated population. Cardiovascular outcomes were not tested. |
Expert Commentary
I regard this study as promising proof of pharmacodynamic activity, not evidence that an oral PCSK9 inhibitor is ready to replace established treatment. The LDL reductions are substantial, but the approximately eighty percent headline includes rosuvastatin and must not be attributed to laroprovstat alone. The placebo-corrected estimates describe the additional effect after a statin run-in. Can I use this with my patients? Not as a prescribing basis from this phase 1 report; it can explain the rationale for further research in patients needing additional lipid lowering. The central limitation is the small, selected population observed for only twenty-eight days of combined treatment. Participants had already demonstrated a response to rosuvastatin, which further limits extrapolation to broader lipid clinics. Safety was the primary objective, and the absence of serious adverse events does not erase the discontinuations for rhythm abnormalities and liver enzyme elevation. Those observations need proportionate follow-up rather than either dismissal or premature attribution of causality. AstraZeneca funding and extensive manufacturer-affiliated authorship should also remain explicit. I would keep this study separate from later development trials and ask for larger, longer comparisons that characterise tolerability, sustained LDL lowering and clinically important cardiovascular outcomes before making claims about treatment substitution or improved adherence.
References
Vega RB, O'Mahony G, Barbour AM, et al. Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients. Circulation. 2026;153(25):1999-2010. doi:10.1161/CIRCULATIONAHA.125.075973. PMID: 42137960.
